TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01179360

Intervention type: OTHER
Intervention: Integrated FDG PET/CT
Description: Optimized PET/CT imaging with dedicated head-and-neck protocol
Study: NCT03620422

Intervention type: OTHER
Group type: OTHER
Intervention: Mannitol
Description: Mannitol-Induced Cough Challenge

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mannitol
Description: Mannitol-Induced Cough Challenge

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mannitol
Description: Mannitol-Induced Cough Challenge

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol 5mg/mL
Description: Nebulized salbutamol given prior to Mannitol-Induced Cough Challenge

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9% Inhl 3Ml
Description: Nebulized 0.9% saline given prior to Mannitol-Induced Cough Challenge
Study: NCT00525135

Intervention type: DRUG
Group type: OTHER
Intervention: Valproic Acid
Description: OUTLINE: This is a pilot study.~Patients receive valproic acid daily for 16 weeks. Dose increases on Days 4 and 8; dose remains the same for weeks 2-10. All patients will undergo a Thyrogen® (thyrotropin alfa for injection) RAI scan at entry to the study and after completion of 10 weeks of valproic acid treatment.~Quality of life is assessed at the end of every week through a study diary.~Patients are followed at 1, 2, 4, 6, 8, 10, 12, 14, 16, and 17 (Schedule 1) weeks. Patients return for follow-up at 3, 6, and 12 months.

Intervention type: DRUG
Group type: OTHER
Intervention: Valproic Acid
Description: OUTLINE: This is a pilot study.~Patients receive valproic acid daily for 16 weeks. Dose increases on Days 4 and 8; dose remains the same for weeks 2-10. All patients will undergo a Thyrogen® (thyrotropin alfa for injection) RAI scan at entry to the study and after completion of 10 weeks of valproic acid treatment.~Quality of life is assessed at the end of every week through a study diary.~Patients are followed at 1, 2, 4, 6, 8, 10, 12, 14, 16, and 17 (Schedule 1) weeks. Patients return for follow-up at 3, 6, and 12 months.
Study: NCT03327584

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthrocentesis
Description: Athrocentesis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthrocentesis
Description: Athrocentesis
Study: NCT04100122

Intervention type: PROCEDURE
Intervention: Blood drawing
Description: Blood drawn will be done once using 15 mL of blood volume (Serum or plasma samples will be collected during the routine follow up of level of sIgE to wheat or during the oral food challenge test which intravenous insertion routinely prepared in case of the emergency reaction occurred). The specimen will be transferred to the Icahn School of Medicine at Mount Sinai, New York, USA for Laboratory processing (Luminex-based peptide assay)

Intervention type: PROCEDURE
Intervention: Blood drawing
Description: Blood drawn will be done once using 15 mL of blood volume (Serum or plasma samples will be collected during the routine follow up of level of sIgE to wheat or during the oral food challenge test which intravenous insertion routinely prepared in case of the emergency reaction occurred). The specimen will be transferred to the Icahn School of Medicine at Mount Sinai, New York, USA for Laboratory processing (Luminex-based peptide assay)

Intervention type: PROCEDURE
Intervention: Blood drawing
Description: Blood drawn will be done once using 15 mL of blood volume (Serum or plasma samples will be collected during the routine follow up of level of sIgE to wheat or during the oral food challenge test which intravenous insertion routinely prepared in case of the emergency reaction occurred). The specimen will be transferred to the Icahn School of Medicine at Mount Sinai, New York, USA for Laboratory processing (Luminex-based peptide assay)
Study: NCT02002884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (8 Units per kg body weight)
Description: Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Mode of administration: intramuscular injection into spastic muscles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (6 Units per kg body weight)
Description: Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Mode of administration: intramuscular injection into spastic muscles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (2 Units per kg body weight)
Description: Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Mode of administration: intramuscular injection into spastic muscles.
Study: NCT00462670

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OPC-41061(Tolvaptan)
Description: 0, 15mg of OPC-41061 per day for 7days p.o. administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-41061(Tolvaptan)
Description: 0, 15mg of OPC-41061 per day for 7days p.o. administration
Study: NCT03498222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Administered at a fixed dose of 1200 mg (equivalent to an average body weight-based dose of 15mg/kg) by intravenous (IV) infusion every 3 weeks (21 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Administered at a fixed dose of 1200 mg (equivalent to an average body weight-based dose of 15mg/kg) by intravenous (IV) infusion every 3 weeks (21 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Administered at a fixed dose of 1200 mg (equivalent to an average body weight-based dose of 15mg/kg) by intravenous (IV) infusion every 3 weeks (21 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered at a fixed dose of 500mg/m2 by IV infusion every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered at a fixed dose of 500mg/m2 by IV infusion every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered at a fixed dose of 500mg/m2 by IV infusion every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered at a fixed dose of AUC5 by IV infusion every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered at a fixed dose of AUC5 by IV infusion every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered at a fixed dose of AUC5 by IV infusion every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI PEG20
Description: Administered by intramuscular (IM) injection to patients once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI PEG20
Description: Administered by intramuscular (IM) injection to patients once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI PEG20
Description: Administered by intramuscular (IM) injection to patients once weekly.
Study: NCT03933111

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: local sound velocity measurement
Description: All patients are scanned by Fuji film su-9000 ultrasonic system. After the lesions are found, local sound velocity measurement technology will be used to measure the sound velocity in the lesions.Pathology diagnosis or clinical follow-up results will be regard as diagnostic gold standard divide the patients into pancreatic cancer and pancreatic cancer group.
Study: NCT04461795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fremanezumab-Vfrm 225 MG/1.5 ML Subcutaneous Solution [AJOVY]
Description: 225 MG/1.5 ML Subcutaneous Solution
Study: NCT01681108

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle counseling
Description: Individualized meal planning and exercise regimen sessions will be developed for each participant
Study: NCT01226563

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IK-5001
Description: 4 mL (+/- 0.2 mL) administered through intracoronary slow bolus injection over 15 to 30 seconds at least 2 days after PCI but within 5 days of onset of symptoms.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: 4 mL (+/- 0.2 mL) slow bolus, intracoronary injection of saline solution will be administered over 15 to 30 seconds at least 2 days after percutaneous coronary intervention (PCI) but within 5 days of onset of symptoms.
Study: NCT00970125

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: video
Description: outline of the goals of care
Study: NCT01134601

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244
Study: NCT02986061

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Urinary catheter
Study: NCT03244462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1834845
Description: Single oral dose (IR \[immediate release\] tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1834845
Description: Single oral dose (IR \[immediate release\] tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1834845
Description: Single oral dose (IR \[immediate release\] tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1834845
Description: Single oral dose (IR \[immediate release\] tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1834845
Description: I.v. infusion of \[13C6\]-labeled BAY1834845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1834845
Description: I.v. infusion of \[13C6\]-labeled BAY1834845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Single dose of commercially available MTX

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Single dose of commercially available MTX
Study: NCT01262443

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency Ablation
Description: Radiofrequency ablation by a standard 4mm irrigated flexible tip catheter
Study: NCT04398446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemp-based CBD
Description: 3x Daily dosing for 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: 3x Daily dosing for 12 weeks
Study: NCT02884414

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cutaneous stimulation
Description: A non-invasive external device that will be placed on the leg of the subject. The device consists of a sensing module to determine specific points in the gait cycle, a processor to analyze signal from the sensor, and a stimulus module to provide feedback to the subject.
Study: NCT00529919

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Weight loss
Description: Weight loss study including consumption of either 22-25 g of medium chain triglyceride oil or olive oil

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Weight loss
Description: Weight loss study including consumption of either 22-25 g of medium chain triglyceride oil or olive oil
Study: NCT01729117

Intervention type: OTHER
Group type: OTHER
Intervention: Meal Replacement
Description: 5 Meal Replacements/day will be given for 3 months and then 1/day for 9 months.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Description: Standard Care only
Study: NCT00602680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSR180711C
Description: duration of treatment: 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSR180711C
Description: duration of treatment: 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSR180711C
Description: duration of treatment: 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: donepezil
Description: duration of treatment: 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: duration of treatment: 4 weeks
Study: NCT00560664

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous chondrocytes transplantation
Description: Cartilage was harvested, then transferred for cell isolation and culture. Cells are suspended in agarose and transferred to cylindrical molds and surgically implanted 4 weeks later.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mosaicoplasty
Description: Osteochondral patch are sampled and then implanted during the same surgical procedure
Study: NCT02873130

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telepractice Global Voice Prevention Model

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-person Global Voice Prevention Model

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Telepractice, Vocal Hygiene and Vocal Education
Study: NCT03353259

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid and Tocilizumab
Description: The first intervention is Tranexamic acid, The second intervention is Tocilizumab

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid and Tocilizumab
Description: The first intervention is Tranexamic acid, The second intervention is Tocilizumab
Study: NCT02815787

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SP2086
Description: In the A sequence Glyburide was taken at 5mg qd dose on Days1,4,5,6,7 and 8; SP2086 will be administered orally (by mouth) as 200mg on Days 8.In the B sequence was that SP2086 was taken at 200mg qd dose on Days1,4,5,6,7 and 8;Glyburide will be administered orally (by mouth) as 200mg on Days 8.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SP2086
Description: In the A sequence Glyburide was taken at 5mg qd dose on Days1,4,5,6,7 and 8; SP2086 will be administered orally (by mouth) as 200mg on Days 8.In the B sequence was that SP2086 was taken at 200mg qd dose on Days1,4,5,6,7 and 8;Glyburide will be administered orally (by mouth) as 200mg on Days 8.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyburide
Description: In the A sequence Glyburide was taken at 5mg qd dose on Days1,4,5,6,7 and 8; SP2086 will be administered orally (by mouth) as 200mg on Days 8.In the B sequence was that SP2086 was taken at 200mg qd dose on Days1,4,5,6,7 and 8;Glyburide will be administered orally (by mouth) as 200mg on Days 8.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyburide
Description: In the A sequence Glyburide was taken at 5mg qd dose on Days1,4,5,6,7 and 8; SP2086 will be administered orally (by mouth) as 200mg on Days 8.In the B sequence was that SP2086 was taken at 200mg qd dose on Days1,4,5,6,7 and 8;Glyburide will be administered orally (by mouth) as 200mg on Days 8.
Study: NCT01678014

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation(DBS)
Description: Deep Brain Stimulation(DBS)is a neurosurgical procedure which include the implantation of deep brain electrodes and the connect to an implantable pulse generator (IPG) that is implanted below the collarbone.
Study: NCT02880774

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mandibular nonspecific mobilization
Description: The mobilization will be held with the individual in supine position, by a trained and experienced therapist, where using disposable gloves, will position the first finger on the last molar, performing intermittently mobilization during 1 minute, will be held five repetitions. Going on a break during the repetition, in that the individual will carry out 15 times language exercises on the palate. With regard to mobilizing joint side, this will be previously set by means of the RDC/TMD and may be unilateral or bilateral basis, depending on the diagnosis. The therapist will remain in orthostatic in opposite side the mobilization to prevent any pressure on the jaw. The treatment will last for 4 weeks, 3 times a week, for a total of 12 sessions.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound detuned,
Description: Will be held the identical positioning to group A with the individual supine on the stretcher, used ultrasound equipment detuned on the region of the face with the presence of TMD. The procedures of this group will have a duration of 4 weeks, 3 times a week, for a total of 12 sessions.
Study: NCT02256982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study: NCT01678014

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Capsulotomy
Study: NCT02256982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgical Resection and Lymphadenectomy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation Therapy
Study: NCT04164043

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Recovery Program
Description: 12-week community-based recreation therapy
Study: NCT03761030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-DOPA
Description: We will be using generic sinemet 25/100 tablets in this study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: 25/100 placebo tablets
Study: NCT01844661

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CELYVIR
Study: NCT03381300

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ovarian tissue cryopreservation
Description: Laparoscopic unilateral oophorectomy followed by cryopreservation of ovarian cortex tissue
Study: NCT04313179

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: Mozart lullaby music

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: 0.5 ml of 24% Sucrose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sucrose
Description: 0.5 ml of 24% Sucrose
Study: NCT03103373

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional monitor
Description: Patients underwent non-cardiac surgery will be monitoring by regular monitors

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Patients will be monitoring by regular monitors plus echocardiography
Study: NCT03224611

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: light wand
Description: The light wand is used as a stylet of the flexible LMA. When the investigator inserts the flexible LMA in light wand group, the correct position of the LMA is confirmed by the light.
Study: NCT05146544

Intervention type: OTHER
Intervention: Heart Rate Recording
Description: During the APA session, HR was digitized at 1Hz (using custo guard, Custo Med GmbH). The ratio between the APA session HR and exercise test HRpeak was used to assess the intensity of effort.

Intervention type: OTHER
Intervention: Heart Rate Recording
Description: During the APA session, HR was digitized at 1Hz (using custo guard, Custo Med GmbH). The ratio between the APA session HR and exercise test HRpeak was used to assess the intensity of effort.
Study: NCT03764878

Intervention type: DIAGNOSTIC_TEST
Intervention: functional MRI
Description: Participants will undergo a functional MRI using multiple imaging modalities.

Intervention type: DIAGNOSTIC_TEST
Intervention: functional MRI
Description: Participants will undergo a functional MRI using multiple imaging modalities.

Intervention type: DIAGNOSTIC_TEST
Intervention: functional MRI
Description: Participants will undergo a functional MRI using multiple imaging modalities.
Study: NCT03486587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacillus Cereus tablets
Description: Bacillus Cereus tablets was taken two tablets three times a day.
Study: NCT03919786

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: topical local anesthesia of pulmonary vein combined with vagus nerve block
Description: Injecting 1% lidocaine 1.5ml+0.375% ropivacaine 1.5ml into vascular sheaths of all pulmonary vein of the surgery side at the beginning of surgery operation.~Wrapping all pulmonary vein of the surgery side with cotton sheet infiltrated with 1% lidocaine+0.375% ropivacaine at the end of surgery operation.~Blocking vagus nerve above the aortic vein on the right side of the trachea with 1% lidocaine 1ml+0.375% ropivacaine 1ml after exposing the pleural apex.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: topical local anesthesia of pulmonary vein combined with vagus nerve block
Description: Injecting 1% lidocaine 1.5ml+0.375% ropivacaine 1.5ml into vascular sheaths of all pulmonary vein of the surgery side at the beginning of surgery operation.~Wrapping all pulmonary vein of the surgery side with cotton sheet infiltrated with 1% lidocaine+0.375% ropivacaine at the end of surgery operation.~Blocking vagus nerve above the aortic vein on the right side of the trachea with 1% lidocaine 1ml+0.375% ropivacaine 1ml after exposing the pleural apex.
Study: NCT02648971

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single Portal Knee Arthroscopy
Description: Patients in Group 1 will undergo knee arthroscopy using a single portal.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two Portal Knee Arthroscopy
Description: Patients in Group 2 will undergo knee arthroscopy using two portals.
Study: NCT03107819

Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma and urine metabolomics
Description: Through the use of high-pressure liquid chromatography and mass spectrometry, quantitative measurements of targeted metabolites associated with amino acids, methylation, acetylation and the tricarboxylic acid (TCA) cycle will be analyzed on the blood and urine specimens.
Study: NCT00509002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: 250 mg by mouth once a day, every day, at about same time in morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: 250 mg by mouth once a day, every day, at about same time in morning.
Study: NCT00146250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Description: Substitution of Nitrous oxide for Nitrogen as balance gas in inspired gas mixture

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Description: Substitution of Nitrous oxide for Nitrogen as balance gas in inspired gas mixture
Study: NCT03450655

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 10-week aerobic exercise program
Description: An aerobic exercise program consisting of 45-60 minute sessions 3 times a week for 10 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 10-week aerobic exercise program
Description: An aerobic exercise program consisting of 45-60 minute sessions 3 times a week for 10 weeks.